Skip to main content
Top
Published in: Tumor Biology 1/2014

01-01-2014 | Research Article

DNA polymerase β mutations and survival of patients with esophageal squamous cell carcinoma in Linzhou City, China

Authors: Min Li, Wenqiao Zang, Yuanyuan Wang, Yunyun Ma, Xiaoyan Xuan, Jimin Zhao, Lulu Liu, Ziming Dong, Guoqiang Zhao

Published in: Tumor Biology | Issue 1/2014

Login to get access

Abstract

Linzhou City in northern China has a high incidence of esophageal squamous cell carcinoma (ESCC). This study retrospectively analyzed the data of 231 cases with ESCC collected from 1998 to 2012. Mutations of DNA polymerase β (polβ) gene in the ESCC samples from patients in Linzhou City were examined by amplifying polβ cDNA by RT-PCR followed by cloning and sequencing. Mutations in polβ were found in 105 cases (45.9 %). Nine types of mutations were identified in the polβ cDNA; the most common were 177–234 nt deletion (11.3 %), 462 nt G → T (9.1 %), and 648 nt G → C (6.9 %). Mutations in polβ appeared to be associated with TNM status (P = 0.048). Follow-up data was used for survival analysis. The overall 5-year survival rate of the 231 patients was 37.4 %; the rate for patients with wild-type (WT) polβ was 41.8 %. Compared with the WT polβ group, the median survival for patients with specific mutations (177–234 nt deletion, 462 nt G → T, or 613 nt A → T) was significantly shorter (all P = 0.000), and the 5-year survival rate decreased to 0 %. Patients with the 648 nt G → C mutation had improved survival (P = 0.000) with a 5-year survival rate of 100 %. Our results identified nine types of mutations within polβ cDNA in ESCC patients with four mutations related to patient survival.
Literature
2.
go back to reference Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80(6):827–41.PubMedCrossRef Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80(6):827–41.PubMedCrossRef
3.
go back to reference Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer. 1996;69(3):225–35. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer. 1996;69(3):225–35.
4.
go back to reference Idriss HT, Al-Assar O, Wilson SH. DNA polymerase beta. Int J Biochem Cell Biol. 2002;34(4):321–4.PubMedCrossRef Idriss HT, Al-Assar O, Wilson SH. DNA polymerase beta. Int J Biochem Cell Biol. 2002;34(4):321–4.PubMedCrossRef
5.
go back to reference Bergoglio V, Pillaire MJ, Lacroix-Triki M, Raynaud-Messina B, Canitrot Y, Bieth A, et al. Deregulated DNA polymerase beta induces chromosome instability and tumorigenesis. Cancer Res. 2002;62(12):3511–4.PubMed Bergoglio V, Pillaire MJ, Lacroix-Triki M, Raynaud-Messina B, Canitrot Y, Bieth A, et al. Deregulated DNA polymerase beta induces chromosome instability and tumorigenesis. Cancer Res. 2002;62(12):3511–4.PubMed
6.
go back to reference Canitrot Y, Frechet M, Servant L, Cazaux C, Hoffmann JS. Overexpression of DNA polymerase beta: a genomic instability enhancer process. FASEB J. 1999;13(9):1107–11.PubMed Canitrot Y, Frechet M, Servant L, Cazaux C, Hoffmann JS. Overexpression of DNA polymerase beta: a genomic instability enhancer process. FASEB J. 1999;13(9):1107–11.PubMed
7.
go back to reference Canitrot Y, Cazaux C, Fréchet M, Bouayadi K, Lesca C, Salles B, et al. Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A. 1998;95(21):12586–90.PubMedCentralPubMedCrossRef Canitrot Y, Cazaux C, Fréchet M, Bouayadi K, Lesca C, Salles B, et al. Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A. 1998;95(21):12586–90.PubMedCentralPubMedCrossRef
8.
go back to reference Sliwinski T, Ziemba P, Morawiec Z, Kowalski M, Zadrozny M, Blasiak J. Polymorphisms of the DNA polymerase beta gene in breast cancer. Breast Cancer Res Treat. 2007;103(2):161–6.PubMedCrossRef Sliwinski T, Ziemba P, Morawiec Z, Kowalski M, Zadrozny M, Blasiak J. Polymorphisms of the DNA polymerase beta gene in breast cancer. Breast Cancer Res Treat. 2007;103(2):161–6.PubMedCrossRef
9.
go back to reference Lang T, Dalal S, Chikova A, DiMaio D, Sweasy JB. The E295K DNA polymerase beta gastric cancer-associated variant interferes with base excision repair and induces cellular transformation. Mol Cell Biol. 2007;27(15):5587–96.PubMedCentralPubMedCrossRef Lang T, Dalal S, Chikova A, DiMaio D, Sweasy JB. The E295K DNA polymerase beta gastric cancer-associated variant interferes with base excision repair and induces cellular transformation. Mol Cell Biol. 2007;27(15):5587–96.PubMedCentralPubMedCrossRef
10.
go back to reference Tan XH, Zhao M, Pan KF, Dong Y, Dong B, Feng GJ, et al. Frequent mutation related with overexpression of DNA polymerase beta in primary tumors and precancerous lesions of human stomach. Cancer Lett. 2005;220(1):101–14.PubMedCrossRef Tan XH, Zhao M, Pan KF, Dong Y, Dong B, Feng GJ, et al. Frequent mutation related with overexpression of DNA polymerase beta in primary tumors and precancerous lesions of human stomach. Cancer Lett. 2005;220(1):101–14.PubMedCrossRef
11.
go back to reference Eydmann ME, Knowles MA. Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer. Cancer Genet Cytogenet. 1997;93(2):167–71.PubMedCrossRef Eydmann ME, Knowles MA. Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer. Cancer Genet Cytogenet. 1997;93(2):167–71.PubMedCrossRef
12.
go back to reference Dalal S, Hile S, Eckert KA, Sun KW, Starcevic D, Sweasy JB. Prostate-cancer-associated I260M variant of DNA polymerase beta is a sequence-specific mutator. Biochemistry. 2005;44(48):15664–73.PubMedCrossRef Dalal S, Hile S, Eckert KA, Sun KW, Starcevic D, Sweasy JB. Prostate-cancer-associated I260M variant of DNA polymerase beta is a sequence-specific mutator. Biochemistry. 2005;44(48):15664–73.PubMedCrossRef
13.
go back to reference Albertella MR, Lau A, O’Connor MJ. The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst). 2005;4(5):583–93.CrossRef Albertella MR, Lau A, O’Connor MJ. The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst). 2005;4(5):583–93.CrossRef
14.
go back to reference Sobol RW, Foley JF, Nyska A, Davidson MG, Wilson SH. Regulated over-expression of DNA polymerase beta mediates early onset cataract in mice. DNA Repair (Amst). 2003;2(5):609–22.CrossRef Sobol RW, Foley JF, Nyska A, Davidson MG, Wilson SH. Regulated over-expression of DNA polymerase beta mediates early onset cataract in mice. DNA Repair (Amst). 2003;2(5):609–22.CrossRef
15.
go back to reference Khanra K, Panda K, Bhattacharya C, Mitra AK, Sarkar R, Bhattacharyya N. Association of two polymorphisms of DNA polymerase beta in exon-9 and exon-11 with ovarian carcinoma in India. Asian Pac J Cancer Prev. 2012;13(4):1321–4.PubMedCrossRef Khanra K, Panda K, Bhattacharya C, Mitra AK, Sarkar R, Bhattacharyya N. Association of two polymorphisms of DNA polymerase beta in exon-9 and exon-11 with ovarian carcinoma in India. Asian Pac J Cancer Prev. 2012;13(4):1321–4.PubMedCrossRef
16.
go back to reference Khanra K, Bhattacharya C, Bhattacharyya N. Association of a newly identified variant of DNA polymerase beta (polβΔ63–123, 208–304) with the risk factor of ovarian carcinoma in India. Asian Pac J Cancer Prev. 2012;13(5):1999–2002.PubMedCrossRef Khanra K, Bhattacharya C, Bhattacharyya N. Association of a newly identified variant of DNA polymerase beta (polβΔ63–123, 208–304) with the risk factor of ovarian carcinoma in India. Asian Pac J Cancer Prev. 2012;13(5):1999–2002.PubMedCrossRef
17.
go back to reference Iwanaga A, Ouchida M, Miyazaki K, Hori K, Mukai T. Functional mutation of DNA polymerase beta found in human gastric cancer–inability of the base excision repair in vitro. Mutat Res. 1999;435(2):121–8.PubMedCrossRef Iwanaga A, Ouchida M, Miyazaki K, Hori K, Mukai T. Functional mutation of DNA polymerase beta found in human gastric cancer–inability of the base excision repair in vitro. Mutat Res. 1999;435(2):121–8.PubMedCrossRef
18.
go back to reference Zhao GQ, Wang T, Zhao Q, Yang HY, Tan XH, Dong ZM. Mutation of DNA polymerase beta in esophageal carcinoma of different regions. World J Gastroenterol. 2005;11(30):4618–22.PubMed Zhao GQ, Wang T, Zhao Q, Yang HY, Tan XH, Dong ZM. Mutation of DNA polymerase beta in esophageal carcinoma of different regions. World J Gastroenterol. 2005;11(30):4618–22.PubMed
19.
go back to reference Dong Z, Zhao G, Zhao Q, Yang H, Xue L, Tan X, et al. A study of DNA polymerase beta mutation in human esophageal cancer. Zhonghua Yi Xue Za Zhi. 2002;82(13):899–902.PubMed Dong Z, Zhao G, Zhao Q, Yang H, Xue L, Tan X, et al. A study of DNA polymerase beta mutation in human esophageal cancer. Zhonghua Yi Xue Za Zhi. 2002;82(13):899–902.PubMed
20.
go back to reference Dong ZM, Zheng NG, Wu JL, Li SK, Wang YL. Difference in expression level and localization of DNA polymerase beta among human esophageal cancer focus, adjacent and corresponding normal tissues. Dis Esophagus. 2006;19(3):172–6.PubMedCrossRef Dong ZM, Zheng NG, Wu JL, Li SK, Wang YL. Difference in expression level and localization of DNA polymerase beta among human esophageal cancer focus, adjacent and corresponding normal tissues. Dis Esophagus. 2006;19(3):172–6.PubMedCrossRef
21.
go back to reference Li M, Zang W, Wang Y, Li Y, Ma Y, Wang N, et al. DNA polymerase β promoter mutations and transcriptional activity in esophageal squamous cell carcinoma. Tumour Biol. 2013. doi:10.1007/s13277-013-0898-5. Li M, Zang W, Wang Y, Li Y, Ma Y, Wang N, et al. DNA polymerase β promoter mutations and transcriptional activity in esophageal squamous cell carcinoma. Tumour Biol. 2013. doi:10.​1007/​s13277-013-0898-5.
22.
go back to reference Wang T, Zang W, Ma Y, Li M, Xuan X, Wang N, et al. DNA polymerase beta promoter mutations affect gene transcription, translation and the sensitivity of esophageal cancer cells to cisplatin treatment. Mol Biol Rep. 2013;40(2):1333–9.PubMedCrossRef Wang T, Zang W, Ma Y, Li M, Xuan X, Wang N, et al. DNA polymerase beta promoter mutations affect gene transcription, translation and the sensitivity of esophageal cancer cells to cisplatin treatment. Mol Biol Rep. 2013;40(2):1333–9.PubMedCrossRef
23.
go back to reference Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17(1):2–9.PubMedCrossRef Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17(1):2–9.PubMedCrossRef
24.
go back to reference Qi YJ, Chao WX, Chiu JF. An overview of esophageal squamous cell carcinoma proteomics. J Proteomics. 2012;75(11):3129–37.PubMedCrossRef Qi YJ, Chao WX, Chiu JF. An overview of esophageal squamous cell carcinoma proteomics. J Proteomics. 2012;75(11):3129–37.PubMedCrossRef
25.
go back to reference Ke L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970–90. Int J Cancer. 2002;102(3):271–4.PubMedCrossRef Ke L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970–90. Int J Cancer. 2002;102(3):271–4.PubMedCrossRef
26.
go back to reference Deziel NC, Wei WQ, Abnet CC, Qiao YL, Sunderland D, Ren JS, et al. A multi-day environmental study of polycyclic aromatic hydrocarbon exposure in a high-risk region for esophageal cancer in China. J Expo Sci Environ Epidemiol. 2013;23(1):52–9.PubMedCentralPubMedCrossRef Deziel NC, Wei WQ, Abnet CC, Qiao YL, Sunderland D, Ren JS, et al. A multi-day environmental study of polycyclic aromatic hydrocarbon exposure in a high-risk region for esophageal cancer in China. J Expo Sci Environ Epidemiol. 2013;23(1):52–9.PubMedCentralPubMedCrossRef
27.
28.
go back to reference Li LW, Li YY, Li XY, Zhang CP, Zhou Y, Lu SH. A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma. BMC Cancer. 2011;11:52.PubMedCentralPubMedCrossRef Li LW, Li YY, Li XY, Zhang CP, Zhou Y, Lu SH. A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma. BMC Cancer. 2011;11:52.PubMedCentralPubMedCrossRef
29.
30.
go back to reference Guo Z, Zheng L, Dai H, Zhou M, Xu H, Shen B. Human DNA polymerase beta polymorphism, Arg137Gln, impairs its polymerase activity and interaction with PCNA and the cellular base excision repair capacity. Nucleic Acids Res. 2009;37(10):3431–41.PubMedCentralPubMedCrossRef Guo Z, Zheng L, Dai H, Zhou M, Xu H, Shen B. Human DNA polymerase beta polymorphism, Arg137Gln, impairs its polymerase activity and interaction with PCNA and the cellular base excision repair capacity. Nucleic Acids Res. 2009;37(10):3431–41.PubMedCentralPubMedCrossRef
31.
go back to reference Yamtich J, Nemec AA, Keh A, Sweasy JB. A germline polymorphism of DNA polymerase beta induces genomic instability and cellular transformation. PLoS Genet. 2012;8(11):e1003052.PubMedCentralPubMedCrossRef Yamtich J, Nemec AA, Keh A, Sweasy JB. A germline polymorphism of DNA polymerase beta induces genomic instability and cellular transformation. PLoS Genet. 2012;8(11):e1003052.PubMedCentralPubMedCrossRef
Metadata
Title
DNA polymerase β mutations and survival of patients with esophageal squamous cell carcinoma in Linzhou City, China
Authors
Min Li
Wenqiao Zang
Yuanyuan Wang
Yunyun Ma
Xiaoyan Xuan
Jimin Zhao
Lulu Liu
Ziming Dong
Guoqiang Zhao
Publication date
01-01-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1077-4

Other articles of this Issue 1/2014

Tumor Biology 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine